December 02, 2016
3 min watch
Save
This article is more than 5 years old. Information may no longer be current.
VIDEO: Mease discusses effectiveness of tofacitinib against PsA
WASHINGTON — At the American College of Rheumatology Annual Meeting, Philip J. Mease, MD, rheumatologist at Swedish Medical Center and clinical professor at the University of Washington, discussed tofacitinib — an oral Janus kinase inhibitor — and its effectiveness against psoriatic arthritis as demonstrated in two studies.
Mease mentioned that both doses of tofacitinib — 5 mg or 10 mg twice per day — were effective in treating all clinical domains. In addition, he said there was evidence of non-progression on radiographs and there were no new adverse events compared with what has been seen in previous studies of tofacitinib against rheumatoid arthritis.